[go: up one dir, main page]

MX2023008364A - Metodo para el tratamiento de enfermedades renales cronicas. - Google Patents

Metodo para el tratamiento de enfermedades renales cronicas.

Info

Publication number
MX2023008364A
MX2023008364A MX2023008364A MX2023008364A MX2023008364A MX 2023008364 A MX2023008364 A MX 2023008364A MX 2023008364 A MX2023008364 A MX 2023008364A MX 2023008364 A MX2023008364 A MX 2023008364A MX 2023008364 A MX2023008364 A MX 2023008364A
Authority
MX
Mexico
Prior art keywords
treatment
chronic kidney
kidney diseases
diseases
chronic
Prior art date
Application number
MX2023008364A
Other languages
English (en)
Inventor
Raphaël Darteil
Jacky Vonderscher
Fabiola Terzi
Pietro Scalfaro
Hugo Girma
Original Assignee
Enyo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enyo Pharma filed Critical Enyo Pharma
Publication of MX2023008364A publication Critical patent/MX2023008364A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método para el tratamiento de enfermedades renales crónicas.
MX2023008364A 2021-01-14 2022-01-13 Metodo para el tratamiento de enfermedades renales cronicas. MX2023008364A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305036 2021-01-14
EP21306466 2021-10-20
PCT/EP2022/050592 WO2022152773A1 (en) 2021-01-14 2022-01-13 Method for treating chronic kidney diseases

Publications (1)

Publication Number Publication Date
MX2023008364A true MX2023008364A (es) 2023-07-26

Family

ID=80122149

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008364A MX2023008364A (es) 2021-01-14 2022-01-13 Metodo para el tratamiento de enfermedades renales cronicas.

Country Status (10)

Country Link
US (1) US20230165853A1 (es)
EP (1) EP4277630A1 (es)
JP (1) JP2024503861A (es)
KR (1) KR20230130715A (es)
AU (1) AU2022208190A1 (es)
CA (1) CA3201686A1 (es)
IL (1) IL304221A (es)
MX (1) MX2023008364A (es)
WO (1) WO2022152773A1 (es)
ZA (1) ZA202307779B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026002833A1 (en) * 2024-06-24 2026-01-02 Enyo Pharma Ethanolamine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
MX2017012893A (es) * 2015-04-07 2018-01-15 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapias combinadas.
CA3016875C (en) * 2016-03-11 2023-08-22 Intercept Pharmaceuticals, Inc. 3-desoxy derivative and pharmaceutical compositions thereof
AR108711A1 (es) * 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
WO2018051229A1 (en) * 2016-09-14 2018-03-22 Novartis Ag Novel regimes of fxr agonists
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
KR20200097091A (ko) * 2019-02-07 2020-08-18 전남대학교산학협력단 신장질환 예방 및 치료용 약학조성물 및 건강기능성식품
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2021009331A1 (en) * 2019-07-18 2021-01-21 Enyo Pharma Improved treatment using eyp001
TW202143958A (zh) * 2020-03-18 2021-12-01 美商梅塔克林公司 用於治療疾病之法尼醇x(farnesoid x)受體促效劑
US12030861B1 (en) * 2023-07-13 2024-07-09 Enyo Pharma L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof

Also Published As

Publication number Publication date
WO2022152773A1 (en) 2022-07-21
KR20230130715A (ko) 2023-09-12
CA3201686A1 (en) 2022-07-21
EP4277630A1 (en) 2023-11-22
AU2022208190A9 (en) 2025-03-13
US20230165853A1 (en) 2023-06-01
ZA202307779B (en) 2025-12-17
IL304221A (en) 2023-09-01
AU2022208190A1 (en) 2023-07-06
JP2024503861A (ja) 2024-01-29

Similar Documents

Publication Publication Date Title
CO2021017845A2 (es) Proteínas multiespecíficas
MX2023007581A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
CL2021000355A1 (es) Inhibidores de ptpn11
CU20210029A7 (es) Inhibidores de proteína tirosina fosfatasa shp2 útiles en el tratamiento de enfermedades
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
CL2020002277A1 (es) Formas cristalinas de compuesto de triazolopirimidina (divisional 201803734)
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
EA201892740A2 (ru) Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk)
MX2019001448A (es) Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
MX2018015654A (es) Cromatografía de interacción hidrofóbica para la purificación de oligonucleótidos.
EA201891446A1 (ru) Молекулы полиспецифичных антител, имеющие специфичность к tnf-альфа, il-17a и il-17f
MX385138B (es) Inmunomoduladores de aminoacilindazol para el tratamiento de enfermedades autoinmunes.
CL2021001363A1 (es) Métodos de tratamiento de enfermedades con inhibidores de magl.
MX2019007161A (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
BR112018075039A2 (pt) métodos de tratamento da síndrome de prader-willi
CL2021000797A1 (es) Una ayuda para la deposición de fluidos agrícolas.
CL2018002756A1 (es) Un proceso mejorado para la preparación de tartrato de butorfanol.
MX2023008364A (es) Metodo para el tratamiento de enfermedades renales cronicas.
CL2021000902A1 (es) Método para la fabricación de gemas sintéticas.
BR112017025264A2 (pt) tratamento de prurido
CL2023001137A1 (es) Procedimiento para la purificación de pleuromutilinas
BR112022008856A2 (pt) Terapia combinada para doenças musculares